NEW YORK, October 30, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Natus Medical Inc. (NASDAQ: BABY), Merit Medical Systems, Inc. (NASDAQ: MMSI), Invacare Corporation (NYSE: IVC), and Zalicus Inc. (NASDAQ: ZLCS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celgene Corporation Research Report

On October 24, 2013, Celgene Corporation (Celgene) released its Q3 2013 financial results. The Company's revenues for the quarter went up by 18.0% YoY to $1.7 billion. Net income for Q3 2013 was $372.5 million or $0.87 per diluted share, compared to net income of $424.2 million or $0.97 per diluted share in Q3 2012. Commenting on the results, Bob Hugin, Chairman and CEO of Celgene stated, "Celgene had an exceptional third quarter with continued operating momentum across our global businesses highlighted by approvals for IMNOVID® for relapsed and refractory multiple myeloma in Europe and ABRAXANE® for pancreatic cancer in the U.S. In the fourth quarter we will present new data on apremilast in psoriatic arthritis at ACR and on REVLIMID® in newly diagnosed multiple myeloma at ASH." The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7f47_CELG]

Natus Medical Inc. Research Report

On October 24, 2013, Natus Medical Inc. (Natus) released its Q3 2013 financial results. The Company reported revenue of $85.4 million, up 5.4% YoY, while gross profit was $51.3 million, reflecting an increase of 15.2% YoY. Net income for Q3 2013 was $6.3 million or $0.20 per diluted share, compared to net loss of $1.7 million or $0.06 per diluted share in Q3 2012. Commenting on the results, Jim Hawkins, President and CEO of the Company said, "I am very pleased to report our third quarter results. We exceeded our revenue and earnings guidance and improved our non-GAAP gross profit margin to 61%. This was driven by stronger than expected results from both our neurology and newborn care businesses. Both our domestic and international results exceeded our expectations and we saw noticeable improvements in the European market. We also ended the quarter with a higher order backlog." The Full Research Report on Natus Medical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/03ac_BABY]

Merit Medical Systems, Inc. Research Report

On October 23, 2013, Merit Medical Systems, Inc. (Merit Medical) released its Q3 2013 financial results. The Company reported revenues of $115.2 million for the quarter, an increase of 20.1% YoY. Gross profit for Q3 2013 was $51.0 million, reflecting an increase of 12.6% YoY. Net income was $5.6 million or $0.13 per diluted share, compared to net income of $7.2 million or $0.17 per diluted share in Q3 2012. Commenting on the results, Fred P. Lampropoulos, Chairman and CEO, said, "Although we had anticipated lower revenue growth due to seasonal considerations, we are very pleased with the sales and operational results for the third quarter. Overall revenue growth of 20% was driven by core product growth of 11%. This growth, combined with lower SG&A expenses sequentially and year-to-date, delivered results we are pleased with." The Full Research Report on Merit Medical Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/338a_MMSI]

Invacare Corporation Research Report

On October 24, 2013, Invacare Corporation (Invacare) released its Q3 2013 financial results. The Company's net sales decreased 5.6% to $341.2 million, while gross profit declined 11.5% YoY to $96.8 million during the quarter. Net earnings were $16.1 million or $0.50 per diluted share, up compared to net earnings of $2.9 million or $0.09 per diluted share in Q3 2012. Commenting on the results, Gerald B. Blouch, President and CEO stated, "The strength of our European business segment continued to be the highlight of our 2013 financial performance, as the segment had a strong third quarter. The remaining three business segments experienced ongoing pressures primarily related to the consent decree, lack of new product introductions and unfavorable sales mix favoring lower margin products. As a result, the overall third quarter 2013 financial performance resulted in adjusted loss per share of $0.18 compared to adjusted earnings per shareof $0.05 in the third quarter of 2012." The Full Research Report on Invacare Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e086_IVC]

Zalicus Inc. Research Report

On October 15, 2013, Zalicus Inc. (Zalicus) announced that it has received a notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC. As per the notice, the Company has regained compliance with Nasdaq Marketplace Rule 5550 relating to the maintenance of a minimum $1.00 bid price, and the matter has now been closed. The Full Research Report on Zalicus Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cbb5_ZLCS]

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner